Low-Dose Radiotherapy for Non-Oncologic Indications

OR (95% CI): 3 mos: 0.69 (0.22 to 2.17) 6 mos: 0.57 (0.18 to 1.81) 12 mos: 1.23 (0.37 to 4.12) Mean Treatment Difference (95% CI): 3 mos: -3.7 (-11.5 to 4.0) 6 mos: -6.4 (-11.9 to 0.3) 12 mos: 3.7 (-4.3 to 11.6) Mean Treatment Differences (95% CI): 3 mos: -6.5 (-13.4 to 0.4) 6 mos: -3.6 (-10.7 to 3.5) 12 mos: -1.2 (-8.2 to 5.9) Mean Treatment Differences (95% CI): 3 mos: -0.1 (-1.2 to 1.1) 6 mos: 0.3 (-0.9 to 1.5) 12 mos: -0.1 (-1.2 to 1.1) NR Mahler et al (2018)16,; Ende et al (2020)18, OMERACT-OARSI WOMAC Pain WOMAC Function PGA LDRT (n=27) 3 mos: 44% 6 mos: 41% 12 mos: 52% Any reaction: 10 (37%) Skin reactions: 5 (19%) Nail reactions: 4 (15%) Fatigue: 6 (22%) Other reactions: 3 (11%) Serious AEs: 0% Sham (n=27) 3 mos: 43% 6 mos: 35% 12 mos: 44% Any reaction: 10 (36%) Skin reactions: 5 (18%) Nail reactions: 3 (11%) Fatigue: 4 (14%) Other reactions: 4 (14%) Serious AEs: 3 (11%) <td style="width: 15.0726%;" width="96"